Tuesday, May 30, 2023

IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein

 

As the immunity provided by these vaccines rapidly wanes, their ability to prevent hospitalization and severe disease in individuals with comorbidities has recently been questioned, and increasing evidence has shown that, as with many other vaccines, they do not produce sterilizing immunity, allowing people to suffer frequent re-infections....

[R]ecent investigations have found abnormally high levels of IgG4 in people who were administered two or more injections of the mRNA vaccines… [E]merging evidence suggests that the reported increase in IgG4 levels detected after repeated vaccination with the mRNA vaccines may not be a protective mechanism; rather, it constitutes an immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses. Increased IgG4 synthesis due to repeated mRNA vaccination with high antigen concentrations may also cause autoimmune diseases, and promote cancer growth and autoimmune myocarditis in susceptible individuals....

It is worth noting that there are conflicting pieces of information about the level of protection offered by these vaccines. Although the Center for Disease Control (CDC) in the United States has stated that throughout the pandemic, mortality rates have been higher in the unvaccinated than in the vaccinated, the data in the United Kingdom contradict the CDC’s findings. Specifically, the Office for National Statistics (ONS) in the United Kingdom has reported that from April to mid-November 2021, deaths in unvaccinated people were higher in comparison with vaccinated people who had received a second vaccine dose. However, from the end of November 2021 to December 2022, this situation reverted: deaths were higher in vaccinated people who received a third vaccine dose compared with the unvaccinated.

https://pubmed.ncbi.nlm.nih.gov/37243095/


No comments: